GCG and pulmonary arterial hypertension: Newer hypoglycaemic agents such as the Sodium-Glucose Transporter Type 2 (SGT2) agonists or Glucagon-Like Peptide-1 (GLP-1) agonists may potentially offer similar or greater benefits in PAH patients.